Akari’s AKTX-101 ADC Wins ASCO Acceptance for KRAS-mutant Cancer Synergy
Akari Therapeutics secured its first ASCO abstract acceptance for AKTX-101’s RNA-splicing modulator ADC showing combination synergy with a KRAS inhibitor in KRAS-mutant pancreatic cancers. The full abstract will be published online May 21, 2026, ahead of planned Phase 1 initiation in late 2026/early 2027.
1. ASCO Abstract Acceptance
Akari Therapeutics received its first acceptance at the ASCO Annual Meeting for an abstract titled “Combination synergy of spliceosome modulator ADC with a K-Ras inhibitor in KRAS–mutated pancreatic cancers,” scheduled for online publication May 21, 2026.
2. Preclinical Efficacy and Synergy
The AKTX-101 ADC leverages the PH1 spliceosome modulator payload to disrupt RNA splicing and has shown significant tumor cell death and synergy with KRAS inhibitors in preclinical pancreatic cancer models, as well as potential combinability with checkpoint inhibitors.
3. Development and Timeline
Akari is advancing AKTX-101 toward Phase 1 clinical trials, targeting initiation in late 2026/early 2027, supported by IND enabling studies, and is exploring additional tumor indications beyond pancreatic cancer using the same payload platform.